FMP

FMP

Enter

KMPH - KemPharm, Inc.

photo-url-https://images.financialmodelingprep.com/symbol/KMPH.png

KemPharm, Inc.

KMPH

NASDAQ

Inactive Equity

KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077 which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase I clinical trial. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. KemPharm, Inc. has collaboration and license agreement, with KVK-Tech, Inc. and Commave Therapeutics SA. The company was incorporated in 2006 and is headquartered in Celebration, Florida.

5.81 USD

-0.02 (-0.344%)

Historical Prices

From:

To:

We are unable to load the chart at this time.

fmp-logo

About

ceo

Mr. Richard W. Pascoe

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077 which is under Phase II clinical trial for the tre...

CIK

0001434647

ISIN

US4884452065

CUSIP

488445206

Address

1180 Celebration Boulevard

Phone

321 939 3416

Country

US

Employee

24

IPO Date

Apr 16, 2015

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

KMPH Financial Summary

CIK

0001434647

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

488445206

ISIN

US4884452065

Country

US

Price

5.81

Beta

2.16

Volume Avg.

229.54k

Market Cap

200.47M

Shares

-

52-Week

4.0-6.92

DCF

32.91

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-6.38

P/B

-

Website

https://kempharm.com

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

Latest KMPH News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep